51 s2.0 S0246037815458002.pdf


Aperçu du fichier PDF 51-s2-0-s0246037815458002.pdf

Page 1...13 14 15


Aperçu texte


Sclérose latérale amyotrophique 17-078-A-10

[69] Pugdahl K, Fuglsang-Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, Labarre-Vila A, et al. A prospective multicentre study on
sural nerve action potentials in ALS. Clin Neurophysiol 2008;119:
1106–10.
[70] Pradat PF. Atrophie bulbo-spinale liée à l’X : une maladie rare mais un
diagnostic différentiel fréquent de la sclérose latérale amyotrophique.
Presse Med 2014;43:580–6.
[71] de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J,
et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol
2008;119:497–503.
[72] Sasaki S. Sporadic lower motor neuron disease with a snake eyes appearance on the cervical anterior horns by MRI. Clin Neurol Neurosurg
2015;136:122–31.
[73] Lebouteux MV, Franques J, Guillevin R, Delmont E, Lenglet T, Bede
P, et al. Revisiting the spectrum of lower motor neuron diseases with
snake eyes appearance on magnetic resonance imaging. Eur J Neurol
2014;21:1233–41.
[74] Sage CA, Peeters RR, Gorner A, Robberecht W, Sunaert S. Quantitative
diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage
2007;34:486–99.
[75] Pradat PF, El Mendili MM. Neuroimaging to investigate multisystem
involvement and provide biomarkers in amyotrophic lateral sclerosis.
Biomed Res Int 2014;2014:467560.
[76] Foerster BR, Dwamena BA, Petrou M, Carlos RC, Callaghan
BC, Churchill CL, et al. Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review
and individual patient data meta-analysis. Acad Radiol 2013;20:
1099–106.
[77] El Mendili MM, Chen R, Tiret B, Pelegrini-Issac M, Cohen-Adad J,
Lehericy S, et al. Validation of a semiautomated spinal cord segmentation method. J Magn Reson Imaging 2015;41:454–9.
[78] El Mendili MM, Cohen-Adad J, Pelegrini-Issac M, Rossignol S,
Morizot-Koutlidis R, Marchand-Pauvert V, et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral
sclerosis. PLoS One 2014;9:e95516.
[79] Suhy J, Miller RG, Rule R, Schuff N, Licht J, Dronsky V, et al. Early
detection and longitudinal changes in amyotrophic lateral sclerosis by
(1)H MRSI. Neurology 2002;58:773–9.
[80] Carew JD, Nair G, Andersen PM, Wuu J, Gronka S, Hu X,
et al. Presymptomatic spinal cord neurometabolic findings in SOD1positive people at risk for familial ALS. Neurology 2011;77:
1370–5.
[81] Konrad C, Henningsen H, Bremer J, Mock B, Deppe M, Buchinger
C, et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res
2002;143:51–6.
[82] Poujois A, Schneider FC, Faillenot I, Camdessanche JP, Vandenberghe
N, Thomas-Anterion C, et al. Brain plasticity in the motor network is
correlated with disease progression in amyotrophic lateral sclerosis.
Hum Brain Mapp 2013;34:2391–401.
[83] Habert MO, Lacomblez L, Maksud P, El Fakhri G, Pradat JF, Meininger
V. Brain perfusion imaging in amyotrophic lateral sclerosis: extent of
cortical changes according to the severity and topography of motor
impairment. Amyotroph Lateral Scler 2007;8:9–15.
[84] Pagani M, Chio A, Valentini MC, Oberg J, Nobili F, Calvo A, et al.
Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis.
Neurology 2014;83:1067–74.

[85] Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al.
Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.
[86] Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A,
Van Damme P, et al. EFNS guidelines on the clinical management of
amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task
force. Eur J Neurol 2012;19:360–75.
[87] Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D,
Johnston W, et al. Practice parameter update: the care of the patient
with amyotrophic lateral sclerosis: multidisciplinary care, symptom
management, and cognitive/behavioral impairment (an evidence-based
review): report of the Quality Standards Subcommittee of the American
Academy of Neurology. Neurology 2009;73:1227–33.
[88] Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with
amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards
Subcommittee of the American Academy of Neurology. Neurology
2009;73:1218–26.
[89] Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg
JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004;63:1364–70.
[90] Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the
treatment of sialorrhoea in ALS: serious side effects of a transductal
approach. J Neurol Neurosurg Psychiatry 2001;70:417–8.
[91] Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier
P. Nutritional status is a prognostic factor for survival in ALS patients.
Neurology 1999;53:1059–63.
[92] Bouteloup C, Desport JC, Clavelou P, Guy N, Derumeaux-Burel H, Ferrier A, et al. Hypermetabolism in ALS patients: an early and persistent
phenomenon. J Neurol 2009;256:1236–42.
[93] Abdelnour-Mallet M, Verschueren A, Guy N, Soriani MH, Chalbi M,
Gordon P, et al. Safety of home parenteral nutrition in patients with
amyotrophic lateral sclerosis: a French national survey. Amyotroph
Lateral Scler 2011;12:178–84.
[94] Gordon PH, Meininger V. How can we improve clinical trials in amyotrophic lateral sclerosis? Nat Rev Neurol 2011;7:650–4.
[95] Aggarwal S, Cudkowicz M. ALS drug development: reflections from
the past and a way forward. Neurotherapeutics 2008;5:516–27.
[96] Gordon P, Corcia P, Meininger V. New therapy options for amyotrophic
lateral sclerosis. Expert Opin Pharmacother 2013;14:1907–17.
[97] Meininger V, Pradat PF, Corse A, al Sarraj S, Rix BB, Caress JB,
et al. Safety, pharmacokinetic, and functional effects of the nogo-a
monoclonal antibody in amyotrophic lateral sclerosis: a randomized,
first-in-human clinical trial. PLoS One 2014;9:e97803.
[98] Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll
L, et al. Activation of fast skeletal muscle troponin as a potential
therapeutic approach for treating neuromuscular diseases. Nat Med
2012;18:452–5.
[99] Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases.
Trends Mol Med 2012;18:634–43.
[100] Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B,
et al. Multimodal actions of neural stem cells in a mouse model of
ALS: a meta-analysis. Sci Transl Med 2012;4, 165ra164.
[101] Mattis VB, Svendsen CN. Induced pluripotent stem cells: a new revolution for clinical neurology? Lancet Neurol 2011;10:383–94.

P.-F. Pradat.
Département des maladies du système nerveux, Centre référent maladies rares sclérose latérale amyotrophique (SLA), Hôpital de la Salpêtrière, 47, boulevard
de l’Hôpital, 75013 Paris, France.
CNRS, Inserm, Laboratoire d’imagerie biomédicale, Sorbonne Universités, UPMC Université Paris-6, 75012 Paris, France.
P. Corcia.
Centre de ressources et de compétences sclérose latérale amyotrophique (SLA), Fédération des centres SLA Tours-Limoges, LITORALS, CHRU Bretonneau, 2,
boulevard Tonnellé, 37044 Tours cedex 1, France.
V. Meininger (vincent.meininger@aphp.fr).
Réseau de la sclérose latérale amyotrophique en Île-de-France (SLA-IDF), Hôpital de la Salpêtrière, 47, boulevard de l’Hôpital, 75013 Paris, France.
Toute référence à cet article doit porter la mention : Pradat PF, Corcia P, Meininger V. Sclérose latérale amyotrophique. EMC - Neurologie 2016;13(2):1-15
[Article 17-078-A-10].

Disponibles sur www.em-consulte.com
Arbres
décisionnels

Iconographies
supplémentaires

Vidéos/
Animations

Documents
légaux

Information
au patient

Informations
supplémentaires

EMC - Neurologie

Document téléchargé de ClinicalKey.fr par Centre de Recherche sur Information Scientifique et Technique Consortium septembre 25, 2016.
Pour un usage personnel seulement. Aucune autre utilisation n´est autorisée. Copyright ©2016. Elsevier Inc. Tous droits réservés.

Autoévaluations

Cas
clinique

15